UCB to Acquire Candid Therapeutics for up to $2.2 Billion

Why It Matters

The acquisition gives UCB immediate access to a novel T‑cell engager platform, bolstering its position in the fast‑growing autoimmune market and potentially enhancing long‑term earnings growth.

Key Takeaways

• UCB pays $2 bn upfront, up to $200 m milestones.
• Candid’s cizutamig targets B‑cell antigen, in Phase 1 for 10+ autoimmune diseases.
• Deal values at ~55% of UCB’s $4.01 bn market cap.
• UCB’s P/E 12.3, earnings forecast $3.03 per share FY2026.
• Acquisition expands UCB’s immunology pipeline amid strong 15% revenue growth.

Pulse Analysis

UCB’s $2.2 billion purchase of Candid Therapeutics marks one of the larger European biotech deals this year, combining a $2 billion cash payment with up to $200 million in performance‑based milestones. With a 2025 revenue of €7.7 billion—approximately $8.4 billion after conversion—the Belgian‑based firm is leveraging its strong balance sheet to secure cutting‑edge immunology assets. The transaction’s size, roughly half of UCB’s $4.01 billion market cap, underscores the company’s willingness to invest heavily in pipeline diversification despite a modest P/E multiple of 12.3.

Candid’s flagship candidate, cizutamig, is a bispecific antibody that links CD3 on T‑cells to B‑cell maturation antigen on plasma cells, a mechanism gaining traction for both multiple myeloma and autoimmune disorders. The drug is already in Phase 1 trials for over ten autoimmune indications, positioning UCB to tap into a market projected to exceed $200 billion globally by the end of the decade. By integrating this T‑cell engager technology, UCB can accelerate its entry into next‑generation immunotherapies, potentially shortening development timelines and creating synergies with its existing portfolio of monoclonal antibodies.

Analysts view the deal as a strategic bet on long‑term growth rather than immediate earnings impact. While UCB’s shares have delivered a 21% return over the past year, the acquisition pushes the stock slightly above fair‑value estimates, reflecting the premium paid for innovative assets. Nonetheless, the move aligns with a broader wave of consolidation in the biotech sector, where larger pharma companies are acquiring niche developers to stay competitive in an increasingly specialized therapeutic landscape. If cizutamig advances successfully, UCB could see a meaningful uplift in future revenue streams and reinforce its standing as a leader in immunology research.

Deal Summary

UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical‑stage biotech, for up to $2.2 billion, comprising $2 billion in cash upfront and up to $200 million in milestones. The acquisition expands UCB’s T‑cell engager pipeline and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance.